| abstract |
Provided herein are oligomeric compounds having conjugate groups that target apolipoprotein (a) [apo (a)]. In certain embodiments, the oligomeric compound targeting apo (a) is conjugated to N-acetylgalactosamine. Conjugation targeting apo (a) used in reducing apo (a) and treating, preventing, or ameliorating a disease, disorder, or condition associated with apo (a) and / or Lp (a) Oligomeric compounds are also disclosed herein. Certain diseases, disorders, or conditions associated with apo (a) and / or Lp (a) include inflammatory, cardiovascular, and / or metabolic diseases, disorders, or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders, or conditions in individuals in need thereof. [Selection figure] None |